Loading...

Avadel Pharmaceuticals plc

AVDL•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$11.03
$-0.22(-1.96%)

Avadel Pharmaceuticals plc (AVDL) Company Profile & Overview

Explore Avadel Pharmaceuticals plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Avadel Pharmaceuticals plc (AVDL) Company Profile & Overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOGregory J. Divis Jr.

Contact Information

https://www.avadel.com
353 1 901 5201
10 Earlsfort Terrace, Dublin, 2

Company Facts

188 Employees
IPO DateJun 7, 1996
CountryIE
Actively Trading

Frequently Asked Questions

;